Clinical Trial Update: Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial [Phase 2]

View source ↗

Summary

A biomarker-guided Phase 2 trial in non-small cell lung cancer evaluating hyperprogression in patients with PD-L1 expression ≥ 50%. The study is currently not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Università Vita-Salute San Raffaele | Conditions: NSCLC (Non-small Cell Lung Cancer), Hyperprogression | Phase 2 | Status: NOT_YET_RECRUITING